ITMCTR1900002589尚未招募1 期
A Randomized Double-blind Clinical Study for the Effect of Qingzhi Huayu Prescription on SDLDL-C/LDL-C in Patients With Coronary Heart Disease
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 80（—）
- 性别
- All
入选标准
- •Objectives: patients have coronary atherosclerotic heart disease (CAD) with high sdLDL-C.
- •Selection criteria:
- •1) Age between 18 and 80 (including 18 and 80);
- •2) Gender is not limited;
- •3) Coronary angiography showed that the stenosis of any coronary artery exceeded 50%.
- •4) sdLDL-C (>= 52.6mg/dL)
- •5) Patients willing to receive atorvastatin treatment and Traditional Chinese Medicine treatment.
排除标准
- •1) History of statin-related liver lesions and/or myopathy;
- •2) Patients with malignant tumors (excluding those cured);
- •3) Patients with serious diseases of heart, lung, kidney, brain and blood;
- •4) Patients with severe neurological and psychiatric disorders (such as epilepsy, depression, mania, seizures, schizophrenia, etc.);
- •5) Pregnant women and lactating women or those who have pregnancy plans and are unwilling to contracept during the study period;
- •6) Participate in other clinical researchers at the same time;
- •7) Researchers think that it is not suitable for patients to participate in this study.
研究者
相似试验
招募中
3 期
Study to compare the Efficacy and Safety of BCD-264 in the treatment of Relapsed and Refractory Multiple MyelomaCTRI/2024/03/063867JSC BIOCAD, Russia
进行中（未招募）
1 期
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancerProgressive Metastatic Medullary Thyroid CancerMedDRA version: 21.1 Level: PT Classification code 10027105 Term: Medullary thyroid cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003402-40-HUExelixis, Inc.250
进行中（未招募）
1 期
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancerProgressive Metastatic Medullary Thyroid CancerMedDRA version: 21.1Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003402-40-PLExelixis, Inc.250
进行中（未招募）
1 期
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancerEUCTR2013-003402-40-FRExelixis, Inc.188
进行中（未招募）
1 期
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancerProgressive Metastatic Medullary Thyroid CancerMedDRA version: 21.1Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003402-40-SEExelixis, Inc.250